Suzhou Ribo submits EMA phase 2b trial application for Vortosiran in SPAF
PUBT · 2d ago
Share
Listen to the news
- Suzhou Ribo submitted Phase 2b clinical trial application to European Medicines Agency for Vortosiran in stroke prevention in atrial fibrillation.
- Vortosiran (RBD4059) targets factor XI via siRNA, aiming to reduce thromboembolic risk with lower bleeding risk than current anticoagulants.
- Company said Vortosiran Phase 2a trial in coronary artery disease in Europe has been completed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260414-12104359), on April 14, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending